~~<i id='D8B2442FFA'><strike id='D8B2442FFA'><tt id='D8B2442FFA'><pre id='D8B2442FFA'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：hotspot 2025-10-01 13:17:53 Page View：55

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

How are insurers handling Leqembi and related scans?

AdobeWASHINGTON—AweekaftertheFoodandDrugAdministrationgrantedfull,traditionalapprovaltoanewAlzheimer

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Lupron, used to halt puberty in children, may cause lasting health problems

SharissaDerricottoutsideofherparents’homeinLawton,Okla.NickOxfordforKHNForyears,SharissaDerricott,30